3/24
02:03 am
txg
10x Genomics, Inc. (NASDAQ: TXG) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
Low
Report
10x Genomics, Inc. (NASDAQ: TXG) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
3/20
03:14 am
txg
10x Genomics, Inc. (TXG) Stock [Seeking Alpha]
Medium
Report
10x Genomics, Inc. (TXG) Stock [Seeking Alpha]
3/11
06:50 am
txg
2 Reasons to Sell TXG and 1 Stock to Buy Instead [Yahoo! Finance]
Low
Report
2 Reasons to Sell TXG and 1 Stock to Buy Instead [Yahoo! Finance]
3/8
01:33 am
txg
10x Genomics, Inc. (NASDAQ: TXG) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
Medium
Report
10x Genomics, Inc. (NASDAQ: TXG) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
3/7
08:10 pm
txg
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program [Yahoo! Finance]
Medium
Report
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program [Yahoo! Finance]
3/4
12:47 pm
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Citigroup Inc. from $20.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Citigroup Inc. from $20.00 to $15.00. They now have a "buy" rating on the stock.
3/4
08:30 am
txg
Parse Biosciences Advances Plans to Release Single Cell Chromatin Accessibility Products [Yahoo! Finance]
High
Report
Parse Biosciences Advances Plans to Release Single Cell Chromatin Accessibility Products [Yahoo! Finance]
3/3
04:40 pm
txg
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products [Yahoo! Finance]
Medium
Report
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products [Yahoo! Finance]
3/3
04:05 pm
txg
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
Medium
Report
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
2/23
11:30 am
txg
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
Low
Report
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
2/20
02:31 am
txg
10x Genomics, Inc. (NASDAQ: TXG) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
Medium
Report
10x Genomics, Inc. (NASDAQ: TXG) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
2/18
04:44 pm
txg
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference [Yahoo! Finance]
Low
Report
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference [Yahoo! Finance]
2/18
04:05 pm
txg
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference
Low
Report
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference
2/14
09:24 am
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Morgan Stanley from $28.00 to $26.00. They now have an "overweight" rating on the stock.
Low
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Morgan Stanley from $28.00 to $26.00. They now have an "overweight" rating on the stock.
2/14
07:41 am
txg
10x Genomics, Inc. (NASDAQ: TXG) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Medium
Report
10x Genomics, Inc. (NASDAQ: TXG) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
2/13
06:16 pm
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $20.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $20.00 to $18.00. They now have a "buy" rating on the stock.
2/13
02:12 pm
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Citigroup Inc. from $23.00 to $20.00. They now have a "buy" rating on the stock.
Medium
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Citigroup Inc. from $23.00 to $20.00. They now have a "buy" rating on the stock.
2/13
11:21 am
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at JPMorgan Chase & Co. from $14.00 to $12.00. They now have a "neutral" rating on the stock.
Medium
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at JPMorgan Chase & Co. from $14.00 to $12.00. They now have a "neutral" rating on the stock.
2/13
10:00 am
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Stifel Nicolaus from $21.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Stifel Nicolaus from $21.00 to $18.00. They now have a "buy" rating on the stock.
2/13
10:00 am
txg
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at UBS Group AG from $20.00 to $14.00. They now have a "neutral" rating on the stock.
Medium
Report
10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at UBS Group AG from $20.00 to $14.00. They now have a "neutral" rating on the stock.
2/13
07:15 am
txg
10x Genomics, Inc. (NASDAQ: TXG) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $12.00 price target on the stock, down previously from $25.00.
Medium
Report
10x Genomics, Inc. (NASDAQ: TXG) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $12.00 price target on the stock, down previously from $25.00.
2/12
05:19 pm
txg
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations [Yahoo! Finance]
Medium
Report
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations [Yahoo! Finance]
2/12
04:46 pm
txg
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025 [Yahoo! Finance]
Medium
Report
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025 [Yahoo! Finance]
2/12
04:05 pm
txg
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025
Low
Report
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025
2/11
08:51 am
txg
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect [Yahoo! Finance]
Low
Report
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect [Yahoo! Finance]